BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ISTA Pharmaceuticals, Inc. (ISTA) Highlights BEPREVE(R) Clinical Data at the 2011 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting


3/23/2011 8:48:52 AM

IRVINE, CA--(Marketwire - March 22, 2011) - ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced additional results from the Company's BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis. These results were presented in poster sessions at the 2011 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Francisco, CA.

In a poster presentation titled "Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Nonocular Composite Symptom (NOCS) Scores 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis," the Phase 3 studies demonstrated BEPREVE was statistically superior to placebo in reducing summed NOCS scores up to 16 hours after ophthalmic dosing. The data shows support for the clinical effectiveness of BEPREVE in reducing nonocular symptoms associated with allergic conjunctivitis. Authors of the poster were J. I. Williams, T. T. Macejko, M.T. Bergmann, E. J. Meier, M. B. Abelson, J. A. Gow, and T. R. McNamara.

ISTA presented additional effectiveness results from the BEPREVE CAC clinical studies in the following poster presentations at the same meeting:

Bepotastine Besilate Ophthalmic Solution 1.5% Produces Strong Clinical Benefit for Ocular Itching Immediately Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis
Authors: J. C. Clark, J. I. Williams, P. J. Gomes, M. B. Abelson, J. A. Gow, and T. R. McNamara

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Tearing 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis
Authors: J. A. Gow, E. B. McLaurin, F. K. Kurata, M. B. Abelson, J. I. Williams, and T. R. McNamara

ABOUT BEPREVE® (BEPOTASTINE BESILATE OPHTHALMIC SOLUTION) 1.5%
BEPREVE is a non-sedating, highly selective antagonist of the histamine (H1) receptor. It has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues. The compound's primary mechanisms of action are believed to make it an effective treatment against ocular itching associated with allergic conjunctivitis.

BEPREVE was approved by the U.S. Food and Drug Administration in September 2009 for the treatment of ocular itching associated with allergic conjunctivitis. Bepotastine has been approved in Japan for systemic use in the treatment of allergic rhinitis since 2000 and urticaria/pruritus since 2002. It is marketed in Japan by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION®. TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju Pharmaceutical Co., Ltd. exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. In 2006, ISTA licensed the exclusive North American rights from Senju to an eye drop formulation of bepotastine for the treatment of allergic conjunctivitis. In 2007, ISTA licensed the exclusive North American rights to nasal dosage forms of bepotastine from Tanabe Seiyaku and obtained a future right to negotiate for a North American license to oral dosage forms of bepotastine for allergy treatment.

Full prescribing information for BEPREVE is available on ISTA's website at http://www.istavision.com/pdf/Bepreve_insert.pdf.

ABOUT ISTA PHARMACEUTICALS
ISTA Pharmaceuticals, Inc., is the fourth largest and fastest growing branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics. ISTA currently markets four products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The company's development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain, and nasal allergies. Headquartered in Irvine, California, ISTA generated revenues of $156.5 million in 2010. For additional information about ISTA, please visit the corporate website at www.istavision.com.

BEPREVE® is a trademark of ISTA Pharmaceuticals, Inc. TALION® is a trademark of Mitsubishi Tanabe Pharma Corporation.


CONTACTS
For Investor Relations:
Lauren Silvernail
949-788-5302
lsilvernail@istavision.com

Jeanie Herbert
949-789-3159
jherbert@istavision.com

Juliane Snowden
Burns McClellan
212-213-0006
jsnowden@burnsmc.com

For General Media:
Justin Jackson
Burns McClellan
212-213-0006
jjackson@burnsmc.com

For Trade Media:
Tad Heitmann
BioComm Network
714-273-2937
theitmann@BioCommNetwork.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES